Moderna

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna

Moderna Covid-19 vaccine safe and effective in teens

Moderna has announced that its Phase II/III study of its Covid-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of Covid-19 were observed in participants who had received two doses of the Moderna Covid-19… Read More

#Covid-19 #News #Trending News

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #Vaccines

500 million Covid-19 vaccine doses delivered to lowest income countries

Moderna has announced an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of the Covid-19 Vaccine Moderna, including an initial 34 million doses to be delivered in the fourth quarter of 2021. Through this agreement, on behalf of the COVAX Facility, Gavi also retains… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Vaccines

Moderna invests to increase global supply for Covid-19 vaccine

Moderna is to increase supply at its manufacturing facilities, which it expects will increase global 2022 capacity to up to 3 billion doses of its Covid-19 vaccine. This will depend upon the mix between the authorised Moderna Covid-19 vaccine at the 100 μg dose level and potentially lower… Read More

#News

#Clinical trials #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Vaccines

Moderna’s Covid-19 vaccine antibody persistence data published

Biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, Moderna, has had antibody persistence data out to six months following the second Covid-19 vaccine dose published in The New England Journal of Medicine. “We are pleased that this new data shows antibody persistence through six months following the second dose… Read More

#Covid-19 #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna starts vaccine trials on babies and children

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna doses first patients for its next generation COVID-19 vaccine

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News